CoChat

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

Open access
Stockler, Martin R., Harvey, Vernon J., Francis, Prudence A., Byrne, Michael J., Ackland, Stephen P., Fitzharris, Bernie, Van Hazel, Guy, Wilcken, Nicholas R.C., Grimison, Peter S., Nowak, Anna K., Gainford, M. Corona, Fong, Akiko, Paksec, Lisa, Sourjina, Tatiana, Zannino, Diana, Gebski, Val, Simes, R. John, Forbes, John F., Coates, Alan S. · 2011 · Journal of Clinical Oncology
Cited by 152

The DOI matches its Crossref record.

Abstract

Purpose: We compared oral capecitabine, administered intermittently or continuously, versus classical cyclophosphamide, methotrexate, and fluorouracil (CMF) as first-line chemotherapy for women with advanced breast cancer unsuited to more intensive regimens. Patients and Methods: Three hundred twenty-three eligible women were randomly assigned to capecitabine administered intermittently (1,000 mg/m 2 twice daily for 14 of every 21 days; n = 107) or continuously (650 mg/m 2 twice daily for 21 of every 21 days; n = 107), or to classical CMF (oral cyclophosphamide 100 mg/m 2 days 1 to 14 with intravenous methotrexate 40 mg/m 2 and fluorouracil 600 mg/m 2 on days 1 and 8 every 28 days; n = 109). The primary end point was quality-adjusted progression-free survival (PFS); secondary end points included PFS, overall survival (OS), objective tumor response, and adverse events. Intermittent and continuous capecitabine were to be compared first and, if similar (P > .05), combined for definitive comparisons versus CMF. Results: Quality-adjusted PFS (P = .2), objective tumor response rate (20%; P = .8), and PFS (median, 6 months; hazard ratio [HR], 0.86; 95% CI, 0.67 to 1.10; P = .2) were similar in women assigned capecitabine versus CMF. OS was longer in women assigned capecitabine rather than CMF (median, 22 v 18 months; HR, 0.72; 95% CI, 0.55 to 0.94; P = .02). Febrile neutropenia, infection, stomatitis, and serious adverse events were more common with CMF; hand-foot syndrome was more common with capecitabine. Conclusion: Capecitabine improved OS by being similarly active, less toxic, and more tolerable than CMF. Capecitabine is a good first-line chemotherapy option for women with advanced breast cancer who are unsuited to more intensive regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.33.9101

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 152

Metadata

Authors
Stockler, M. R., Harvey, V. J., Francis, P. A., Byrne, M. J., Ackland, S. P., Fitzharris, B., Van Hazel, G., Wilcken, N. R. C., Grimison, P. S., Nowak, A. K., Gainford, M. C., Fong, A., Paksec, L., Sourjina, T., Zannino, D., Gebski, V., Simes, R. J., Forbes, J. F., & Coates, A. S.
Venue
Journal of Clinical Oncology
Published
2011-12-01
Volume
29
Issue
34
Pages
4498-4504
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2171611244
Cited by
152
References
0
FWCI
3.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2010.33.9101
The paper
Stockler, M. R., Harvey, V. J., Francis, P. A., Byrne, M. J., Ackland, S. P., Fitzharris, B., Van Hazel, G., Wilcken, N. R. C., Grimison, P. S., Nowak, A. K., Gainford, M. C., Fong, A., Paksec, L., Sourjina, T., Zannino, D., Gebski, V., Simes, R. J., Forbes, J. F., & Coates, A. S. (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.9101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.